June 5, 2018 09:41 AM EDT
R&D

#AS­CO18: Ab­b­Vie con­vinces one top an­a­lyst that its $6B 'megablock­buster' Ro­va-T is worth­less

John Carroll

Editor & Founder

Ab­b­Vie $AB­BV has man­aged to con­vince at least one promi­nent an­a­lyst that Ro­va-T is ab­solute­ly worth­less, as the com­pa­ny’s vi­sion of a $5 bil­lion earn­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

A service from the Financial Times